PATENT CLAIM ANALYSIS

Application Number: 16287413
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-08
Patent Classification: ["424", "482000"]

Abstract:
A method of treating a subject for a brain disease associated with cognitive impairment, including administering to a subject a chemical substance according to GLN-1062 or salt thereof: wherein the treatment includes transmucosal administration of a therapeutically effective amount of GLN 1062 or salt thereof in the oral cavity of the subject.

Claim (Index 14):
The method according to  claim 13 , wherein the sublingual tablet comprises:\n lactose monohydrate, corn starch, polyvinylpyrrolidone (PVP) and/or magnesium stearate, and optionally with a flavouring agent, or mannitol, sodium starch glycolate, croscarmellose, ascorbic acid and/or magnesium stearate, optionally with a flavouring agent.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 99.0
- Lexical Diversity: 1.375
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15699626', '13861134', '13213960', '11399879', '14189981']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6761600075489208
- 35 USC 102 Novelty (BERT): 0.5071544734063563
- Combined Prediction Score: 0.6592594541346644
- Mean Citation Score: 168.20383399999997
- Max Citation Score: 201.84703
- Similarity Product: 126.83098225110233

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test